483
Cadila Pharmaceuticals LimitedFDA 483 - Cadila Pharmaceuticals Limited - January 20, 2023
Discuss this record with AI
Document or profile
One record shows the event. A profile shows the pattern.
Buy this document for the source file and details behind this single event.
Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.
Record Details
An FDA inspection of Cadila Pharmaceuticals Limited in Ankleshwar, Gujarat, India, revealed a significant issue with laboratory controls. The firm failed to establish the sensitivity of test methods, specifically regarding the determination of chromatographic purity for intermediates. This indicates a deficiency in ensuring the accuracy and reliability of analytical testing procedures.
Open in Dashboard
ID · 5962c1e6-00e1-4d6f-9684-015dde5a5a4c